会社概要
- 正式社名: Croda pharma
- 登録国: United Kingdom
- 住所: Cowick, Snaith, East Cowick, Goole
- 従業員数: 1000 - 4999
説明:
Croda Pharma is a leading partner for developing excipients and supplying high-purity materials for pharmaceutical formulations, offering high-purity excipients that enhance delivery, efficacy and stability of active ingredients, along with high-performing vaccine adjuvants and in-house formulation expertise to navigate drug and vaccine formulation challenges. The company focuses on enabling biologics drug delivery through its adjuvant systems and small molecule, protein and nucleic acid delivery platforms, offering solutions for both human and animal health markets backed by substantial investment in GMP and multi-site EXCiPACT accreditation.
事業活動
賦形剤・添加剤
製造業者受託製造業者(CMO)添加剤サプライヤー
天然抽出物・生薬原料
製造業者受託製造業者(CMO)添加剤サプライヤー
医薬用化学品
製造業者受託製造業者(CMO)添加剤サプライヤー
販売市場
- East Asia: China, Democratic People's Republic of Korea, Mongolia, Republic of Korea, Japan, Taiwan
- South Asia: Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka, Afghanistan, Iran
- Mainland Southeast Asia: Cambodia, Lao People's Democratic Republic, Myanmar, Thailand, Viet Nam, Brunei Darussalam, Indonesia, Malaysia, Philippines, Timor-Leste, Singapore
- Melanesia: Papua New Guinea
- Western Asia: United Arab Emirates, Armenia, Azerbaijan
主要製品/サービス
- 受託・アウトソーシングサービス: Adjuvant Systems for Vaccines
- 賦形剤・添加剤: Excipient: Super Refined™ PEG 400, Excipient: Super Refined™ Polysorbate 80, Excipient: Super Refined™ Polysorbate 20, Excipient: Super Refined™ DEGEE, Excipient: Super Refined™ P35 Caster Oil, Tween™ 80 HP, Super Refined™ PGML, Cholesterol, Crodafos™ CES pharma, Super Refined™ GMCC, Super Refined™ L18 POG, Super Refined™ O18 POG, Excipients for Consumer Health, Super Refined™ Benzyl Alcohol, Super Refined™ DMI, Super Refined™ GTCC, Super Refined™ PEG 300
- 医薬用化学品: Nucleic Acid Delivery for Vaccines and Next-Gen Therapeutics
- バイオ医薬品: Cationic Adjuvant Formulation CAF®
- バイオ医薬品サービス: Bioprocessing solutions and excipients for protein therapeutic formulations
- ATC分類(解剖治療化学分類): ALC-0315
- 先発品原薬: ENT-DSPC, Vaccine Adjuvant: Alhydrogel™, Vaccine Adjuvant: Quil-A™
当社の製品・サービス
Sell · ATC (Anatomical Therapeutic Chemical) Classification
認証
GMP
証明
CPHI & PMEC China 2026
06/2026 – 06/2026
CPHI & PMEC China 2026
評価
(0)
(0)
(0)
(0)
(0)
コメント
フィルター:
並べ替え:
コメントはありません。
評価とコメントを残す